<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Flurazepam</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00690</strong>&#160; (APRD00983)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, illicit</td></tr><tr><th>Description</th><td><p>A benzodiazepine derivative used mainly as a hypnotic. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00690/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00690/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00690.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00690.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00690.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00690.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00690.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00690">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Flurazepam</td><td>Spanish/German</td><td>INN</td></tr><tr><td>Fluraz&#233;pam</td><td>French</td><td>INN</td></tr><tr><td>Flurazepamum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Flurazepam Hydrochloride</strong>
          <div class="cas">36105-20-1</div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000543/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000543/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: PUGVROXLRUQCAF-UHFFFAOYSA-N</li>
              <li>Monoisotopic Mass: 423.128046024</li>
              <li>Average Mass: 424.339</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000543">DBSALT000543</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Dalmadorm</td><td>Meda</td></tr><tr><td>Dalmadorm medium</td><td>Meda</td></tr><tr><td>Dalmane</td><td>Meda</td></tr><tr><td>Felison</td><td>SIT</td></tr><tr><td>Flunox</td><td>Teofarma</td></tr><tr><td>Sompan</td><td>I.C.N.</td></tr><tr><td>Valdorm</td><td>Valeas</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>CAS number</th><td>17617-23-1</td></tr><tr><th>Weight</th><td>Average: 387.878<br>Monoisotopic: 387.151368285</td></tr><tr><th>Chemical Formula</th><td>C<sub>21</sub>H<sub>23</sub>ClFN<sub>3</sub>O</td></tr><tr><th>InChI Key</th><td>SAADBVWGJQAEFS-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C21H23ClFN3O/c1-3-25(4-2)11-12-26-19-10-9-15(22)13-17(19)21(24-14-20(26)27)16-7-5-6-8-18(16)23/h5-10,13H,3-4,11-12,14H2,1-2H3</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-2,3-dihydro-1H-1,4-benzodiazepin-2-one</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CCN(CC)CCN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Benzodiazepines</td></tr><tr><th>Subclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Direct parent</th><td>Benzodiazepines</td></tr><tr><th>Alternative parents</th><td>Fluorobenzenes; Chlorobenzenes; Aryl Fluorides; Aryl Chlorides; Tertiary Carboxylic Acid Amides; Tertiary Amines; Polyamines; Carboxylic Acids; Organofluorides; Organochlorides</td></tr><tr><th>Substituents</th><td>chlorobenzene; fluorobenzene; aryl chloride; benzene; aryl fluoride; aryl halide; tertiary carboxylic acid amide; carboxamide group; tertiary amine; carboxylic acid derivative; carboxylic acid; polyamine; organochloride; organohalogen; organofluoride; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the benzodiazepines. These are organic compounds containing a benzene ring fused to either isomers of diazepine(unsaturated seven-member heterocycle with two nitrogen atoms replacing two carbon atoms).</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For short-term and intermittent use in patients with recurring insomnia and poor sleeping habits</td></tr><tr><th>Pharmacodynamics</th><td>Flurazepam, a benzodiazepine derivative, is a hypnotic agent which does not appear to decrease dream time as measured by rapid eye movements (REM). Furthermore, it decreases sleep latency and number of awakenings for a consequent increase in total sleep time.</td></tr><tr><th>Mechanism of action</th><td>Flurazepam binds to an allosteric site on GABA-A receptors. Binding potentiates the action of GABA on GABA-A receptors by opening the chloride channel within the receptor, causing chloride influx and hyperpolarization.</td></tr><tr><th>Absorption</th><td>Flurazepam hydrochloride is rapidly (30 minutes) absorbed from the gastrointestinal tract</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>83%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Flurazepam is rapidly metabolized and is excreted primarily in the urine. Both hydroxyethyl flurazepam (the major metabolite) and N-desalkyl flurazepam are active. The N-desalkyl metabolite is slowly excreted in the urine as the conjugated form</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Flurazepam</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00882">Hydroxyethyl flurazepam</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/903">Details</a></td></tr><tr><td>Flurazepam</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00933">N-desalkyl flurazepam</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/954">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Flurazepam is rapidly metabolized and is excreted primarily in the urine. Less than 1% of the dose is excreted in the urine as N1-desalkyl-flurazepam.</td></tr><tr><th>Half life</th><td>The mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Coma, confusion, low blood pressure, sleepiness</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>1.0</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9898</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.6115</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.8553</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.9455</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.6624</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Inhibitor
        </td>
        <td>0.6523</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7716</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.7794</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.5194</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7112</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5469</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Inhibitor</td>
        <td>0.5082</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.6347</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.6231</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9132
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.7597
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            1.0
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.5654 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9528
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.7183
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Valeant pharmaceuticals international</li>
<li>Halsey drug co inc</li>
<li>Mutual pharmaceutical co inc</li>
<li>Mylan pharmaceuticals inc</li>
<li>Par pharmaceutical inc</li>
<li>Purepac pharmaceutical co</li>
<li>Sandoz inc</li>
<li>Superpharm corp</li>
<li>Usl pharma inc</li>
<li>Warner chilcott inc</li>
<li>Warner chilcott div warner lambert co</li>
<li>Watson laboratories inc</li>
<li>West ward pharmaceutical corp</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.amerisourcebergen.com">Amerisource Health Services Corp.</a></li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://bryantranchprepack.com">Bryant Ranch Prepack</a></li>
<li><a href="http://www.corepharma.com">Corepharma LLC</a></li>
<li>Direct Dispensing Inc.</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li><a href="http://hjharkinscompanyinc.com">H.J. Harkins Co. Inc.</a></li>
<li>Hl Moore Drug Exchange</li>
<li>Kaiser Foundation Hospital</li>
<li>Lake Erie Medical and Surgical Supply</li>
<li><a href="http://www.legacypackaging.com">Legacy Pharmaceuticals Packaging LLC</a></li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.parpharm.com">Par Pharmaceuticals</a></li>
<li>PCA LLC</li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li>Prepackage Specialists</li>
<li><a href="http://www.prepaksys.com">Prepak Systems Inc.</a></li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li><a href="http://www.udllabs.com">UDL Laboratories</a></li>
<li><a href="http://www.valeant.com">Valeant Ltd.</a></li>
<li><a href="http://www.west-ward.com">West-Ward Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td></td></tr><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00701">Amprenavir</a></td><td>Amprenavir may increase the effect and toxicity of the benzodiazepine, flurazepam.</td></tr><tr><td><a href="/drugs/DB00501">Cimetidine</a></td><td>Cimetidine may increase the effect of the benzodiazepine, flurazepam.</td></tr><tr><td><a href="/drugs/DB00363">Clozapine</a></td><td>Increased risk of toxicity</td></tr><tr><td><a href="/drugs/DB00754">Ethotoin</a></td><td>Ethotoin may increase the metabolism of flurazepam via CYP3A4.</td></tr><tr><td><a href="/drugs/DB00196">Fluconazole</a></td><td>Fluconazole may increase the effect of the benzodiazepine, flurazepam.</td></tr><tr><td><a href="/drugs/DB01319">Fosamprenavir</a></td><td>Fosamprenavir may increase the effect and toxicity of the benzodiazepine, flurazepam.</td></tr><tr><td><a href="/drugs/DB01320">Fosphenytoin</a></td><td>Fosphenytoin may increase the metabolism of flurazepam via CYP3A4.</td></tr><tr><td><a href="/drugs/DB00224">Indinavir</a></td><td>The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, flurazepam.</td></tr><tr><td><a href="/drugs/DB01167">Itraconazole</a></td><td>Itraconazole may increase the effect of the benzodiazepine, flurazepam.</td></tr><tr><td><a href="/drugs/DB01322">Kava</a></td><td>Kava may increase the effect of the benzodiazepine, flurazepam.</td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>Ketoconazole may increase the effect of the benzodiazepine, flurazepam.</td></tr><tr><td><a href="/drugs/DB00532">Mephenytoin</a></td><td>Mephenytoin may increase the metabolism of flurazepam via CYP3A4.</td></tr><tr><td><a href="/drugs/DB00220">Nelfinavir</a></td><td>The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, flurazepam.</td></tr><tr><td><a href="/drugs/DB00338">Omeprazole</a></td><td>Omeprazole may increase the effect of the benzodiazepine, flurazepam.</td></tr><tr><td><a href="/drugs/DB00252">Phenytoin</a></td><td>Phenytoin may increase the metabolism of flurazepam via CYP3A4.</td></tr><tr><td><a href="/drugs/DB00503">Ritonavir</a></td><td>The protease inhibitor, ritonavir, may increase the effect of the benzodiazepine, flurazepam.</td></tr><tr><td><a href="/drugs/DB01232">Saquinavir</a></td><td>The protease inhibitor, saquinavir, may increase the effect of the benzodiazepine, flurazepam.</td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Telithromycin may reduce clearance of Flurazepam. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Flurazepam if Telithromycin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00932">Tipranavir</a></td><td>Tipranavir may decrease the metabolism and clearance of Flurazepam. Consider alternate therapy or monitor for Flurazepam toxic effects if Tipranavir is initiated or dose increased. </td></tr><tr><td><a href="/drugs/DB00427">Triprolidine</a></td><td>The CNS depressants, Triprolidine and Flurazepam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of flurazepam by decreasing its metabolism. Monitor for flurazepam toxicity if voriconazole is initiated or dose increased.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid alcohol.</li>
<li>Take without regard to meals.</li></ul></td></tr></tbody></table>